Zobrazeno 1 - 10 of 31 pro vyhledávání: '"BG Verheggen"'
1
Cost-Effectiveness of Partially Hydrolyzed Whey Protein Formula in the Primary Prevention of Atopic Dermatitis in At-Risk Urban Filipino Infants
Autor: Esen Erdogan-Ciftci, Patrick Detzel, Abhijeet J Bhanegaonkar, BG Verheggen, Rizalina Racquel H. Gonzalez, Maria Victoria Dizon, Erica G. Horodniceanu, Marc F. Botteman
Publikováno v: Value in Health Regional Issues. 3:124-135
ObjectiveTo estimate, from a Filipino societal perspective, the cost-effectiveness of preventing atopic dermatitis (AD) via early nutritional intervention with 100% whey-based partially hydrolyzed formula (PHF-W) versus standard cow’s milk formula
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d06cb21a08999c1c35e6caf04d49bc87
https://doi.org/10.1016/j.vhri.2014.04.001
Zobrazit plný text záznamu
2
Fingolimod reduces direct medical costs compared to natalizumab in patients with relapsing–remitting multiple sclerosis in The Netherlands
Autor: Martijn Groot, W. S. van der Hel, M Marieke Heisen, BG Verheggen, S. T. F. M. Frequin, MJ Treur
Publikováno v: Journal of Medical Economics. 15:1149-1158
To assess the costs of oral treatment with Gilenya® (fingolimod) compared to intravenous infusion of Tysabri® (natalizumab) in patients with relapsing-remitting multiple sclerosis (RRMS) in The Netherlands.A cost-minimization analysis was used to c
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1bc0c8cbed6e9e1b34257db8dc52c93d
https://doi.org/10.3111/13696998.2012.707631
Zobrazit plný text záznamu
4
Estimating the quality-of-life impact and cost-effectiveness of alpha-blocker and anti-muscarinic combination treatment in men with lower urinary tract symptoms related to benign prostatic hyperplasia and overactive bladder
Autor: Marc F. Botteman, MJ Treur, Jeffrey Trocio, Steven A. Kaplan, Richard K. Lee, Michelle M. Lieuw On, BG Verheggen
Publikováno v: Journal of medical economics. 15(3)
A 12-week clinical trial (TIMES) demonstrated that therapy with tolterodine extended release (TOL) + tamsulosin (TAM) provides clinical benefits vs TOL or TAM monotherapy or placebo (PBO) in men with lower urinary tract symptoms (LUTS) including over
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::af1bc06d1223d95894765905c4aad08f
https://pubmed.ncbi.nlm.nih.gov/22332704
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje